Limits...
Metastasis-associated protein 1 is an upstream regulator of DNMT3a and stimulator of insulin-growth factor binding protein-3 in breast cancer

View Article: PubMed Central - PubMed

ABSTRACT

Despite a recognized role of DNA methyltransferase 3a (DNMT3a) in human cancer, the nature of its upstream regulator(s) and relationship with the master chromatin remodeling factor MTA1, continues to be poorly understood. Here, we found an inverse relationship between the levels of MTA1 and DNMT3a in human cancer and that high levels of MTA1 in combination of low DNMT3a status correlates well with poor survival of breast cancer patients. We discovered that MTA1 represses DNMT3a expression via HDAC1/YY1 transcription factor complex. Because IGFBP3 is an established target of DNMT3a, we investigated the effect of MTA1 upon IGFBP3 expression, and found a coactivator role of MTA1/c-Jun/Pol II coactivator complex upon the IGFBP3 transcription. In addition, MTA1 overexpression correlates well with low levels of DNMT3a which, in turn also correlates with a high IGFBP3 status in breast cancer patients and predicts a poor clinical outcome for breast cancer patients. These findings suggest that MTA1 could regulate the expression of IGFBP3 in both DNMT3a-dependent and -independent manner. Together findings presented here recognize an inherent role of MTA1 as a modifier of DNMT3a and IGFBP3 expression, and consequently, the role of MTA1-DNMT3a-IGFBP3 axis in breast cancer progression.

No MeSH data available.


Schematic model showing the repression of DNMT3a by MTA1 through MTA1/HDAC1/YY1 corepressor complex and transcriptional upregulation of IGFBP3 via MTA1/c-jun/Pol II coactivator complex.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5385551&req=5

f8: Schematic model showing the repression of DNMT3a by MTA1 through MTA1/HDAC1/YY1 corepressor complex and transcriptional upregulation of IGFBP3 via MTA1/c-jun/Pol II coactivator complex.

Mentions: We have found that MTA1 chromatin regulator regulates the expression of DNMT3a via MTA1-containing MTA1/HDAC1/YY1 corepressor complex. In addition to its corepressor functions, MTA1 was found to stimulate the expression of IGFBP3 - via recruiting the MTA1/PolII/c-Jun coactivator complex onto the IGFBP3 (Fig. 8). Further this study highlights the clinical significance of MTA1, DNMT3a and IGFBP3 in determining an overall poor prognosis of cancer patients.


Metastasis-associated protein 1 is an upstream regulator of DNMT3a and stimulator of insulin-growth factor binding protein-3 in breast cancer
Schematic model showing the repression of DNMT3a by MTA1 through MTA1/HDAC1/YY1 corepressor complex and transcriptional upregulation of IGFBP3 via MTA1/c-jun/Pol II coactivator complex.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5385551&req=5

f8: Schematic model showing the repression of DNMT3a by MTA1 through MTA1/HDAC1/YY1 corepressor complex and transcriptional upregulation of IGFBP3 via MTA1/c-jun/Pol II coactivator complex.
Mentions: We have found that MTA1 chromatin regulator regulates the expression of DNMT3a via MTA1-containing MTA1/HDAC1/YY1 corepressor complex. In addition to its corepressor functions, MTA1 was found to stimulate the expression of IGFBP3 - via recruiting the MTA1/PolII/c-Jun coactivator complex onto the IGFBP3 (Fig. 8). Further this study highlights the clinical significance of MTA1, DNMT3a and IGFBP3 in determining an overall poor prognosis of cancer patients.

View Article: PubMed Central - PubMed

ABSTRACT

Despite a recognized role of DNA methyltransferase 3a (DNMT3a) in human cancer, the nature of its upstream regulator(s) and relationship with the master chromatin remodeling factor MTA1, continues to be poorly understood. Here, we found an inverse relationship between the levels of MTA1 and DNMT3a in human cancer and that high levels of MTA1 in combination of low DNMT3a status correlates well with poor survival of breast cancer patients. We discovered that MTA1 represses DNMT3a expression via HDAC1/YY1 transcription factor complex. Because IGFBP3 is an established target of DNMT3a, we investigated the effect of MTA1 upon IGFBP3 expression, and found a coactivator role of MTA1/c-Jun/Pol II coactivator complex upon the IGFBP3 transcription. In addition, MTA1 overexpression correlates well with low levels of DNMT3a which, in turn also correlates with a high IGFBP3 status in breast cancer patients and predicts a poor clinical outcome for breast cancer patients. These findings suggest that MTA1 could regulate the expression of IGFBP3 in both DNMT3a-dependent and -independent manner. Together findings presented here recognize an inherent role of MTA1 as a modifier of DNMT3a and IGFBP3 expression, and consequently, the role of MTA1-DNMT3a-IGFBP3 axis in breast cancer progression.

No MeSH data available.